Table 2.
Proportion of subjects seropositive at baseline and end of study and the seroconversion rate.
| Cadila group | Serum group | ||
|---|---|---|---|
| (N = 201) | (N = 100) | Cadila – Serum* | |
| Measles (cut-off: 200 mIU/mL)# | |||
| Subjects seropositive at baseline, n (%) | 144 (71.6%) | 70 (70.0%) | NA |
| Subjects seropositive at end of study, n (%) | 201 (100.0%) | 100 (100.0%) | 0.0%(0.0% – 0.0%) |
| Seroconversion rate, X/Y (%SC) | 57 / 57(100.0%) | 30 / 30(100.0%) | 0.0%(0.0% – 0.0%) |
| Mumps (cut-off: 8 EU/mL)# | |||
| Subjects seropositive at baseline, n (%) | 18 (9.0%) | 10 (10.0%) | NA |
| Subjects seropositive at end of study, n (%) | 190 (94.5%) | 94 (94.0%) | 0.5%(−5.0% – 6.1%) |
| Seroconversion rate, X/Y (%SC) | 172 / 183(94.0%) | 84 / 90(93.3%) | 0.7%(−5.4% – 6.8%) |
| Rubella (cut-off: 8 IU/mL)# | |||
| Subjects seropositive at baseline, n (%) | 16 (8.0%) | 6 (6.0%) | NA |
| Subjects seropositive at end of study, n (%) | 192 (95.5%) | 91 (91.0%) | 4.5%(−1.2% – 10.2%) |
| Seroconversion rate, X/Y (%SC) | 176 / 185(95.1%) | 86 / 94(91.5%) | 3.7%(−2.3% – 9.6%) |
N = Total no. of subjects in PP population
n = No. of subjects seropositive
X = No. of subjects seropositive at end of study among those seronegative at baseline
Y = No. of subject seronegative at baseline and considered for calculating seroconversion rate
*
Data expressed % (95% CI)
#
An antibody titer equal to or greater than the cut-off was defined as seropositive